Tuesday, March 3, 2026

Ipsen nominates Peter Guenter to Board of Directors

Ipsen has appointed Peter Guenter to its Board of Directors, effective 28 January 2026. The co-optation follows the vacancy of Henri Beaufour’s seat.

Background across Merck, Almirall and Sanofi

Guenter brings close to 40 years of leadership experience in the global pharmaceutical industry. Most recently, he served from 2021 to 2025 as Chief Executive Officer of Merck Healthcare and as a member of the Executive Board of Merck Group. Before that, he was CEO of Almirall from 2017, leading a strategic refocus on medical dermatology.

Earlier in his career, he spent more than 20 years at Sanofi in multiple leadership roles and joined the company’s Executive Committee in 2013. He also holds additional board roles across healthcare and private equity.

Board composition and ratification process

Following the appointment, Ipsen’s Board remains at 14 directors, with seven women and seven men. It includes five independent directors and two employee-representative directors.

The company plans to seek shareholder ratification at the next Shareholders’ Meeting. If approved, the appointment would run for the remainder of Henri Beaufour’s term, until the 2027 Shareholders’ Meeting.

Company profile

Ipsen is a global biopharmaceutical company focused on oncology, rare disease and neuroscience. The company is listed in Paris (Euronext: IPN) and has a Sponsored Level I ADR program in the U.S. (ADR: IPSEY). More details are available at ipsen.com.